Skip to content

Activity and safety of first-line pumitamig plus nab-paclitaxel in triple-negative breast cancer: a single-arm, phase 1b/2 trial.

Nov 2026 · The Lancet Oncology · 0 citations
Medicine
View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.